In the original article, there was a mistake in Table 1 as published. The structure of SPR206 was partially incorrect. In the correct structure, R(FA) is (3S)-4-amino-3-(3-chlorophenyl)butanoyl, R1 is absent, and R3 is Dap+. The corrected Table 1 appears below.
Table 1
| Compound | R (FA) | R1 | R2 | R3 | R4 | R5 | R6 | R7 | R8 | R9 | R10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Polymyxin B (PMB) | Methyloctanoyl/methylheptanoyl | -Dab+ | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 2 | Colistin (polymyxin E) | Methyloctanoyl/methylheptanoyl | -Dab+ | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DLeu | -Leu | -Dab+ | -Dab+ | -Thr] |
| 3 | CB-182,804 | 2-chloro-phenylamino-carbonyl | -Dab+ | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 4 | FADDI-002 | Octanoyl | -Dab+ | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DPhe | -Ada | -Dab+ | -Dab+ | -Thr] |
| 5 | FADDI-287 | Octanoyl | -Dab+ | -Thr | -Dap+ | -cy[Dab | -Dab+ | -DLeu | -Abu | -Dab+ | -Dab+ | -Thr] |
| 6 | CA824 | (S)-1-(2-methylpropyl)-piperazine-2-carbonyl+ | – | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 7 | SPR206 | (3S)-4-amino-3-(3-chlorophenyl)butanoyl | – | -Thr | -Dap+ | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 8 | MicuRx-12 | 3-(2,2-dimethyl-butanoyloxy)-propanoyl (ester bond) | -Dab+ | -Thr | -Dab+ | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 9 | NAB739 | Octanoyl | – | -Thr | -DSer | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
| 10 | NAB815 | Octanoyl | -Dab+ | -Thr | -DThr | -cy[Dab | -Dab+ | -DPhe | -Leu | -Abu | -Dab+ | -Thr] |
| 11 | SPR741 (NAB741) | Acetyl | – | -Thr | -DSer | -cy[Dab | -Dab+ | -DPhe | -Leu | -Dab+ | -Dab+ | -Thr] |
The structures of polymyxin B, colistin, and the novel polymyxin derivatives that display improved efficacy in animal infection models (compounds 4-10)a,b.
The structure of one discontinued derivative (compound 3) as well as that of the potentiator compound SPR741 (NAB741) are also shown.
Amino acyl residues that differ from those in polymyxin B are boxed.
Abu, aminobutyryl; Ada, aminodecanoyl; Dap, diaminopropionyl; cy, cyclic portion indicated with brackets; Dab, diaminobutyryl; FA, fatty acyl.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
polymyxin B, colistin, extremely resistant (XDR), Gram-negative bacteria, improved polymyxins
Citation
Vaara M (2019) Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Front. Microbiol. 10:2275. doi: 10.3389/fmicb.2019.02275
Received
06 August 2019
Accepted
18 September 2019
Published
01 October 2019
Volume
10 - 2019
Edited and reviewed by
Aixin Yan, The University of Hong Kong, Hong Kong
Updates
Copyright
© 2019 Vaara.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Martti Vaara martti.vaara@northernantibiotics.com
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
†ORCID: Martti Vaara orcid.org/0000-0002-7971-0560
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.